Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- Check4 days agoChange DetectedThis updates the ClinicalTrials.gov page footer to reflect a newer software/version revision (from v3.5.2 to v3.5.3).SummaryDifference0.0%

- Check11 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedAdded 'Squamous cell carcinoma of the head and neck' to the study's keywords.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check47 days agoChange DetectedNo additions or deletions are observed between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.0%

- Check54 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3, representing a minor metadata update.SummaryDifference0.0%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.